Posts From the monthly archives: "October 2014"

Andrew Conrad, Head of Life Sciences at Google, announced last week at the Wall Street Journal Digital conference that Google is developing a wearable sensor that can receive signals from circulating nanoparticles. The nanoparticles are bound to antibodies against known biomarkers, and after being ingested as a pill, the nanoparticles circulate throughout the body in…(Read More)

Ovarian cancer is the most fatal gynecological cancer, and among the most fatal of all cancer types. The five year survival rate for ovarian cancer is 44.6%, which (remarkably) is exactly half that of breast cancer. This means that while there are over 10 times as many new cases of breast cancer every year…(Read More)

Oxford University this week announced the establishment of the Precision Cancer Medicine Institute (PCMI) with an initial investment of over $175 million. This new institute will carry out research into advanced cancer diagnostic and therapeutic techniques, and is being funded in cooperation with several industry partners, including Roche Diagnostics and GE Healthcare. The focus for…(Read More)

In news from last month’s European Society for Medical Oncology Congress in Madrid, it appears that the United States lags behind the European Union in comprehensiveness of testing for RAS mutations. Experts now agree that expanded RAS testing is needed for patients with metastatic colorectal cancer. Dick Arnold, MD, director of the Department of…(Read More)

I finally had a chance to watch the complete Congressional hearing on LDT regulation that took place several weeks ago. Several interesting things came up which I haven’t seen mentioned anywhere else: – The issue of FDA’s authority to regulate LDTs may not in fact be settled. Congressman Michael Burgess (R, Texas) stated that…(Read More)

A recent article recapping the annual meeting of the America Society of Hospital Pharmacists (ASHP) focuses on how many major hospital systems are establishing pharmacogenomic (PGx) programs to bring personalized medicine to their patients. Cleveland Clinic launched its Personalized Medication Program within the last year, and other personalized medicine programs profiled in the article include…(Read More)


Real-Time COVID R&D Tracking

As COVID-19 infections continue to spread, organizations with technologies or devices that can support new drug, vaccine, or test development have a life-saving contribution to make. The Amplion Intelligence Platform can alert you to new COVID-19 trial activities in real-time and automatically match you to partners who need your unique capabilities immediately. It’s already tomorrow somewhere, so let us help you start today.  Learn More

Request Access